Format
Items per page
Sort by

Send to:

Choose Destination

Results: 16

1.

Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.

Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, Louis TA, Jabs DA, Altaweel MM, Frick KD.

Ophthalmology. 2014 Oct;121(10):1855-62. doi: 10.1016/j.ophtha.2014.04.022. Epub 2014 Jun 5.

PMID:
24908205
2.

Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial.

Sheppard JD Jr, Singh R, McClellan AJ, Weikert MP, Scoper SV, Joly TJ, Whitley WO, Kakkar E, Pflugfelder SC.

Cornea. 2013 Jul 23. [Epub ahead of print]

PMID:
23884332
3.

Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema.

Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, Lightman SL, Thorne JE, Vitale AT, Altaweel MM; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Ophthalmology. 2013 Sep;120(9):1852-9. doi: 10.1016/j.ophtha.2013.01.069. Epub 2013 May 21.

4.

Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.

Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, Katz J, Thorne JE, Lightman SL, Kempen JH; MUST Research Group.

Ophthalmology. 2013 Aug;120(8):1571-9. doi: 10.1016/j.ophtha.2013.01.025. Epub 2013 Apr 16.

5.

Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.

Sen HN, Drye LT, Goldstein DA, Larson TA, Merrill PT, Pavan PR, Sheppard JD, Burke A, Srivastava SK, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group.

Ocul Immunol Inflamm. 2012 Apr;20(2):104-12. doi: 10.3109/09273948.2011.647228.

6.

Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial.

Frick KD, Drye LT, Kempen JH, Dunn JP, Holland GN, Latkany P, Rao NA, Sen HN, Sugar EA, Thorne JE, Wang RC, Holbrook JT; Multicenter Uveitis Steroid Treatment-MUST Trial Research Group.

Invest Ophthalmol Vis Sci. 2012 Mar 9;53(3):1169-76. doi: 10.1167/iovs.11-8259. Print 2012 Mar.

7.

Morphologic assessment for glaucoma in the Multicenter Uveitis Steroid Treatment (MUST) trial.

Gangaputra SS, Altaweel MM, Peng Q, Friedman DS, Rao PK, Foster CS, Kim RY, Reed SB, Srivastava SK, Wong IG, Kempen JH; MUST Trial Research Group.

Ocul Immunol Inflamm. 2011 Aug;19(4):267-74. doi: 10.3109/09273948.2011.583376.

8.

Microbial keratitis trends following refractive surgery: results of the ASCRS infectious keratitis survey and comparisons with prior ASCRS surveys of infectious keratitis following keratorefractive procedures.

Solomon R, Donnenfeld ED, Holland EJ, Yoo SH, Daya S, G├╝ell JL, Mah FS, Scoper SV, Kim T.

J Cataract Refract Surg. 2011 Jul;37(7):1343-50. doi: 10.1016/j.jcrs.2011.05.006.

PMID:
21700112
9.

Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease.

Sheppard JD, Scoper SV, Samudre S.

J Ocul Pharmacol Ther. 2011 Feb;27(1):23-7. doi: 10.1089/jop.2010.0085. Epub 2010 Dec 6.

PMID:
21133792
10.

Modalities to decrease stromal herpes simplex keratitis reactivation rates.

Sheppard JD, Wertheimer ML, Scoper SV.

Arch Ophthalmol. 2009 Jul;127(7):852-6. doi: 10.1001/archophthalmol.2009.163.

PMID:
19597103
11.

Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.

Scoper SV.

Adv Ther. 2008 Oct;25(10):979-94. doi: 10.1007/s12325-008-0107-x. Review.

PMID:
18836691
12.

Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%.

Kaback M, Scoper SV, Arzeno G, James JE, Hua SY, Salem C, Dickerson JE, Landry TA, Bergamini MV; Brinzolamide 1%/Timolol 0.5% Study Group.

Ophthalmology. 2008 Oct;115(10):1728-34, 1734.e1-2. doi: 10.1016/j.ophtha.2008.04.011. Epub 2008 Jun 5.

PMID:
18538406
13.

Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension.

Scoper SV, Kabat AG, Owen GR, Stroman DW, Kabra BP, Faulkner R, Kulshreshtha AK, Rusk C, Bell B, Jamison T, Bernal-Perez LF, Brooks AC, Nguyen VA.

Adv Ther. 2008 Feb;25(2):77-88. doi: 10.1007/s12325-008-0019-9.

PMID:
18309465
14.

Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.

Scoper SV, Berdy GJ, Lichtenstein SJ, Rubin JM, Bloomenstein M, Prouty RE, Vogelson CT, Edwards MR, Waycaster C, Pasquine T, Gross RD, Robertson SM.

Adv Ther. 2007 Nov-Dec;24(6):1221-32.

PMID:
18165204
15.

Use of keratoscopy, slit-lamp biomicroscopy, and retinoscopy in the management of astigmatism after penetrating keratoplasty.

Rowsey JJ, Fowler WC, Terry MA, Scoper SV.

Refract Corneal Surg. 1991 Jan-Feb;7(1):33-41.

PMID:
2043541
16.

Azlocillin levels in human tears and aqueous humor.

Johnson AP, Scoper SV, Woo FL, Caldwell DR, George WJ.

Am J Ophthalmol. 1985 Apr 15;99(4):469-72.

PMID:
3985084
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk